Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance

被引：0
|
作者：
Chaft, J. E. [1 ]
Oxnard, G. R. [1 ]
Miller, V. A. [1 ]
Kris, M. G. [1 ]
Sima, C. S. [1 ]
Riely, G. J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18001
引用
收藏
页数：1
相关论文
共 50 条
  • [1] DISEASE FLARE AFTER TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH EGFR-MUTANT LUNG CANCER AND ACQUIRED RESISTANCE
    Chaft, Jamie E.
    Oxnard, Geoffrey R.
    Miller, Vincent A.
    Kris, Mark G.
    Sima, Camelia S.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S360 - S360
  • [2] Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
    Chaft, Jamie E.
    Oxnard, Geoffrey R.
    Sima, Camelia S.
    Kris, Mark G.
    Miller, Vincent A.
    Riely, Gregory J.
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6298 - 6303
  • [3] Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
    Luo, Jia
    Makhnin, Alex
    Tobi, Yosef
    Ahn, Linda
    Hayes, Sara A.
    Iqbal, Afsheen
    Ng, Kenneth
    Arcila, Maria E.
    Riely, Gregory J.
    Kris, Mark G.
    Yu, Helena A.
    JCO PRECISION ONCOLOGY, 2021, 5 : 55 - 64
  • [4] Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
    Landi, Lorenza
    Tiseo, Marcello
    Chiari, Rita
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Minuti, Gabriele
    Tibaldi, Carmelo
    Salvini, Jessica
    Facchinetti, Francesco
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Catino, Annamaria
    GiajLevra, Matteo
    Crino, Lucio
    de Marinis, Filippo
    Cappuzzo, Federico
    CLINICAL LUNG CANCER, 2014, 15 (06) : 411 - 417
  • [5] Acquired Resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-Mutant lung cancer among Hispanics (CLICaP)
    Zorrilla, A. Cardona
    Arrieta, O.
    Rojas, L.
    Corrales, L.
    Vargas, C.
    Carranza, H.
    Cuello, M.
    Martin, C.
    Rosell, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S15 - S15
  • [6] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Laurila, Niina
    Koivunen, Jussi P.
    MEDICAL ONCOLOGY, 2015, 32 (07)
  • [7] Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
    Heon, Stephanie
    Nishino, Mizuki
    Goldberg, Sarah B.
    Porter, Jennifer
    Sequist, Lecia V.
    Jackman, David Michael
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Niina Laurila
    Jussi P. Koivunen
    Medical Oncology, 2015, 32
  • [9] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Oxnard, G. R.
    Janjigian, Y. Y.
    Arcila, M. E.
    Kris, M. G.
    Ladanyi, M.
    Azzoli, C. G.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345